AR063545A1 - Derivados de tiazoles -1,3 aminosustituidos, composiciones farmaceuticas que las contienen y usos como agentes anticancer - Google Patents

Derivados de tiazoles -1,3 aminosustituidos, composiciones farmaceuticas que las contienen y usos como agentes anticancer

Info

Publication number
AR063545A1
AR063545A1 ARP070104808A ARP070104808A AR063545A1 AR 063545 A1 AR063545 A1 AR 063545A1 AR P070104808 A ARP070104808 A AR P070104808A AR P070104808 A ARP070104808 A AR P070104808A AR 063545 A1 AR063545 A1 AR 063545A1
Authority
AR
Argentina
Prior art keywords
alkylene
alkyl
aryl
heteroaryl
heterocyclyl
Prior art date
Application number
ARP070104808A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR063545A1 publication Critical patent/AR063545A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto que tiene la formula (1) o una sal, solvato, éster, profármaco o estereoisomero farmacéuticamente aceptable del mismo, donde la línea entre cortada indica un enlace opcional y adicional y donde: R1 es H, alquilo, alquenilo, alquinilo, -(alquileno)m-arilo, -(alquileno)m-cicloalquilo, -(alquileno)m-heteroarilo, -(alquileno)m-heterociclilo o -(alquileno)m-heterocilenilo, donde cualquier grupo arilo, cicloalquilo, heteroarilo, heterociclilo o heterociclenilo puede estar opcional e independientemente sustituido en un átomo de carbono anular o de nitrogeno anular con hasta 3 sustituyentes seleccionados entre halo, alquilo, -O-alquilo, -(alquenileno)m-NR(9)2, -C(O)OR7, -CN, -OH, -(alquileno)m-heteroarilo y -(alquileno)m-arilo; y donde cualquier grupo sustituyente arilo o heteroarilo puede estar sustituido con hasta 5 sustituyentes, que pueden ser iguales o diferentes, y se seleccionan entre -halo, -OH, alquilo, -C(O)OH, -C(O)O-alquilo, -N(R9)2, y -O- alquilo; y donde cualquier grupo arilo, cicloalquilo, heteroarilo, heterociclilo o heterociclenilo puede estar opcionalmente fusionado a un grupo arilo, cicloalquilo, heteroarilo, heterociclilo o heterociclenilo; R2 es H, alquilo, arilo, heteroarilo, -C(O)-alquilo o -C(O)-arilo, donde el arilo, heteroarilo o porcion arilo o un grupo -C(O)-arilo puede estar sustituido con hasta 3 sustituyentes, que pueden ser iguales o diferentes, y se seleccionan independientemente entre halo, alquilo, -C(O)OH, y -O-alquilo; cada caso de R3 es independientemente H, alquilo, haloalquilo, hidroxialquilo, -(alquileno)m-C(O)N(R8)2, -(alquileno)m-NHC(O)-R9 o -(alquileno)m-N(R9)2, o R3 y el átomo de carbono anular al cual esta unido se combinan para formar un grupo carbonilo; R4 es H, -alquilo, haloalquilo, hidroxialquilo, -(alquileno)m-C(O)N(R8)2, -(alquileno)m-NHC(O)-R9 o -(alquileno)m-N(R9)2, o R3 y R3a, junto con el átomo de carbono comun al cual cada uno esta unido, se une para formar un grupo carbonilo, cicloalquilo o heterociclilo; R4a es H, -alquilo, haloalquilo, hidroxialquilo, -(alquileno)m-C(O)N(R8)2, -(alquileno)m-NHC(O)-R9 o -(alquileno)m-N(R9)2; cada caso de R5 es independientemente H, -alquilo, -(alquileno)m-arilo, - (alquileno)m-heteroarilo, -(alquileno)m-heterociclilo, -(alquileno)m-N(R9)2, -(alquileno)m-OH, -(alquileno)m-NHC(O)R9, hidroxialquilo, haloalquilo, -C(O)R6, -C(O)OR9, -C(O)-(alquileno)m-N(R9)2, -(alquileno)m-NHC(O)R7, -NHC(O)OR9 o -NHS(O)2R7; R6 es H, alquilo, arilo, heteroarilo o -NHOH; R7 es H, alquilo o haloalquilo; R8 es H, -OH, alquilo, -O-alquilo, o haloalquilo; R9 es H, alquilo, arilo, heterociclilo, heteroarilo o cicloalquilo; R10 es H, -alquilo, haloalquilo, hidroxialquilo, - (alquileno)m-C(O)N(R8)2, -(alquileno)m-NHC(O)R9 o -(alquileno)m-N(R9)2, o R10 y R10a, junto con el átomo de carbono comun al cual cada uno esta unido, se unen para formar un grupo carbonilo, cicloalquilo o heterociclilo; R10a es H, alquilo, haloalquilo, hidroxialquilo, -(alquileno)m-C(O)N(R8)2, -(alquileno)m-NHC(O)-R9 o -(alquileno)m-N(R9)2; cada caso de R11 es independientemente H, alquilo, haloalquilo, hidroxialquilo, -(alquileno)m-C(O)N(R8)2, -(alquileno)m-NHC(O)-R9 o -(alquileno)m- N(R9)2, o R11 y el átomo de carbono anular al cual esta unido se combinan para formar un grupo carbonilo; cada caso de R12 es independientemente H, -(alquileno)m-arilo, -(alquileno)m-heteroarilo, -(alquileno)m-heterociclilo, -S(O)2-alquilo, -S(O)2- arilo, -S(O)2-heteroarilo, hidroxialquilo, -C(O)R9 o -C(O)OR9; Ar es arileno o heteroarileno, donde el arileno o heteroarileno se une mediante 2 cualquiera de sus átomos de carbono anulares adyacentes, y donde el grupo arileno o heteroarileno puede estar opcionalmente sustituido con hasta 4 sustituyentes, que pueden ser iguales o diferentes, y se seleccionan independientemente entre halo, alquilo, alcoxi, ariloxi, -NH2, -NH-alquilo, -N(alquilo)2, -SR8, -S(O)R8, -C(O)R8, -C(O)OR8, -C(O)N(R8)2, - NHC(O)R8, haloalquilo, -CN y NO2, de modo que cuando Ar es tetrahidronaftileno, R3 y r4 son cada uno distinto de hidrogeno; W es -N(R12)2-, -S-, -O- o -C(R5)2-, donde ambos grupos R5 y el átomo de carbono comun al cual están unidos se pueden combinar para formar un grupo cicloalquilo o heterociclilo, cada uno de los cuales puede estar sustituido adicionalmente; Y es H, halo, alquilo o -CN; Z es -C(R8)- o -N-, de modo que cuando está presenta el enlace opcional adicional, Z es -C(R8)-; cada caso de m es independientemente 0 o 1; n es un numero entero que va de 0 a 2; y p es 0 o 1.
ARP070104808A 2006-10-31 2007-10-30 Derivados de tiazoles -1,3 aminosustituidos, composiciones farmaceuticas que las contienen y usos como agentes anticancer AR063545A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85542006P 2006-10-31 2006-10-31

Publications (1)

Publication Number Publication Date
AR063545A1 true AR063545A1 (es) 2009-01-28

Family

ID=39247333

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104808A AR063545A1 (es) 2006-10-31 2007-10-30 Derivados de tiazoles -1,3 aminosustituidos, composiciones farmaceuticas que las contienen y usos como agentes anticancer

Country Status (12)

Country Link
US (1) US8227605B2 (es)
EP (1) EP2078002B1 (es)
JP (1) JP5103604B2 (es)
KR (1) KR20090075869A (es)
CN (1) CN101573345A (es)
AR (1) AR063545A1 (es)
AU (1) AU2007314341B2 (es)
CA (1) CA2668209A1 (es)
IL (1) IL198398A0 (es)
MX (1) MX2009004785A (es)
TW (1) TW200829582A (es)
WO (1) WO2008054701A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163746B2 (en) 2006-04-19 2012-04-24 Astellas Pharma Inc. Azolecarboxamide derivative
AU2008314922B2 (en) 2007-10-24 2013-08-29 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
WO2009058729A2 (en) * 2007-10-29 2009-05-07 Schering Corporation Thiazole carboxamide derivatives and their to treat cancer
CA2703980A1 (en) * 2007-10-29 2009-05-07 Schering Corporation Diamido thiazole derivatives as protein kinase inhibitors
CA2703981A1 (en) * 2007-10-29 2009-05-07 Schering Corporation Heterocyclic urea and thiourea derivatives and methods of use thereof
JP5230035B2 (ja) * 2007-10-29 2013-07-10 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼ阻害剤としてのチアゾール誘導体
UY31679A1 (es) * 2008-03-03 2009-09-30 Inhibidores de cinasa pim y metodos para su uso
US8168794B2 (en) 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
BR122021005861B1 (pt) 2008-12-03 2023-10-24 The Scripps Research Institute Composto, métodos para estabilizar uma célula animal isolada in vitro e para manter a sobrevivência da célula, e, composição
EP2470183B1 (en) 2009-08-26 2015-09-16 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
US8435976B2 (en) * 2009-09-08 2013-05-07 F. Hoffmann-La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
WO2012004217A1 (en) * 2010-07-06 2012-01-12 Novartis Ag Cyclic ether compounds useful as kinase inhibitors
FR2973597B1 (fr) 2011-04-04 2018-05-25 Somfy Sas Partie de boitier electrique ou electronique et procede de fixation d'une telle partie de boitier sur une structure
CN103204824B (zh) * 2012-01-12 2015-04-08 清华大学深圳研究生院 2-氨基噻唑-4-酰胺类衍生物及其制备方法与应用
CN102617582A (zh) * 2012-02-21 2012-08-01 南开大学 三氮唑埃博霉素类似物，其药物组合物及其制备方法和用途
KR20150013548A (ko) 2012-05-21 2015-02-05 노파르티스 아게 키나제 억제제로서의 신규 고리-치환된 n-피리디닐 아미드
KR102427777B1 (ko) 2012-06-26 2022-08-01 델 마 파마슈티컬스 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법
WO2014118186A1 (en) * 2013-01-30 2014-08-07 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
US9993460B2 (en) 2013-07-26 2018-06-12 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
US10221172B2 (en) 2015-01-13 2019-03-05 Vanderbilt University Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2019002074A1 (en) * 2017-06-29 2019-01-03 Bayer Aktiengesellschaft THIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PRMT5
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
AU2020363100A1 (en) * 2019-10-09 2022-05-12 Cothera Bioscience, Inc. Combination therapy for cancers with KRAS mutation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE355841T1 (de) 1997-12-13 2007-03-15 Bristol Myers Squibb Co Verwendung von pyrazolo ( 3,4-b) pyridin als cyclin-abhängige kinase hemmer
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
JP3989175B2 (ja) 1999-04-15 2007-10-10 ブリストル−マイヤーズ スクイブ カンパニー 環状タンパク質チロシンキナーゼ阻害剤
NZ525016A (en) 2000-09-15 2004-10-29 Vertex Pharma Isoxazoles and their use as inhibitors of ERK
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
EP1781647A2 (en) * 2004-07-22 2007-05-09 Astex Therapeutics Limited Thiazole and isothiazole derivatives as protein kinase inhibitors
EP1637529A1 (en) * 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
US8163746B2 (en) * 2006-04-19 2012-04-24 Astellas Pharma Inc. Azolecarboxamide derivative
AU2007314305B2 (en) * 2006-10-31 2013-01-24 Merck Sharp & Dohme Corp. 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
CA2694218A1 (en) * 2007-07-31 2009-02-05 Schering Corporation Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment
CA2703981A1 (en) * 2007-10-29 2009-05-07 Schering Corporation Heterocyclic urea and thiourea derivatives and methods of use thereof
JP5230035B2 (ja) * 2007-10-29 2013-07-10 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼ阻害剤としてのチアゾール誘導体
JP2012509275A (ja) * 2008-11-19 2012-04-19 シェーリング コーポレイション ジアシルグリセロールアシルトランスフェラーゼの阻害薬

Also Published As

Publication number Publication date
IL198398A0 (en) 2010-02-17
WO2008054701A1 (en) 2008-05-08
CN101573345A (zh) 2009-11-04
TW200829582A (en) 2008-07-16
CA2668209A1 (en) 2008-05-08
EP2078002A1 (en) 2009-07-15
JP2010508273A (ja) 2010-03-18
KR20090075869A (ko) 2009-07-09
EP2078002B1 (en) 2013-08-28
MX2009004785A (es) 2009-06-05
US20100055090A1 (en) 2010-03-04
AU2007314341A1 (en) 2008-05-08
US8227605B2 (en) 2012-07-24
AU2007314341B2 (en) 2013-04-11
JP5103604B2 (ja) 2012-12-19

Similar Documents

Publication Publication Date Title
AR063545A1 (es) Derivados de tiazoles -1,3 aminosustituidos, composiciones farmaceuticas que las contienen y usos como agentes anticancer
AR063531A1 (es) Derivados de anilinopiperazina y composicion farmaceutica
AR063721A1 (es) Derivados de anilinopiperazina y composicion farmaceutica
AR068106A1 (es) Derivados de indol 2-carboxi sustituidos y una composicion farmaceutica
AR069083A1 (es) Derivados heterociclicos de 1,3-tiazol inhibidores de proteinquinasas, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento o prevencion de trastornos proliferativos.
AR064429A1 (es) Derivados indolicos con anillo unidos en las posiciones 4,5, composiciones farmaceuticas que los contienen y usos de los mismos en la prevencion y/o tratamiento de infecciones virales.
AR068109A1 (es) Derivados tetraciclicos de indol y una composicion farmaceutica
AR035371A1 (es) Aminotiazoles, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento
AR048537A1 (es) Derivados de nucleosidos para tratar infecciones por virus de hepatitis c.
AR064428A1 (es) Derivados indolicos con anillo unido en las posiciones 4,5 y sus metodos de uso. composiciones farmaceuticas
PE20170775A1 (es) Derivados de benzodiazepina citotoxicos
AR065499A1 (es) Inhibidores de serino proteasas.composiciones farmaceuticas
AR064430A1 (es) Derivados indolicos con anillo unido en las posiciones 5,6 . composiciones farmaceuticas y uso de los mismos.
AR040336A1 (es) Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
AR117264A1 (es) Esteroides neuroactivos y métodos para su uso
AR077328A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
CO5580815A2 (es) Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen
AR067613A1 (es) Inhibidores de adn-pk, uso y sintesis de los mismos
AR068107A1 (es) Derivados indolicos 2,3 sustituidos y una composicion farmaceutica
BRPI0606367A2 (pt) derivados espirocetais e composições farmacêuticas compreendendo os mesmos
AR081848A1 (es) Inhibidores de la proteina ns5a del vhc
DOP2007000079A (es) Compuestos fenil amido heterocíclicos condensados
AR056186A1 (es) Compuesto de imidazo[1,2-a]piridinilo, su uso para la fabricacion de un medicamento y formulacion farmaceutica que lo comprende
GT200600164A (es) Derivados de dihidrobenzofuranos y usos de los mismos
CR8755A (es) Derivado de quinolina fusionada y uso del mismo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal